__NUXT_JSONP__("/drugs/Alemtuzumab", (function(a,b,c,d,e,f,g){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.",inn:b,marketingAuthorisationDate:"2013-09-12 00:00:00",marketingAuthorisationHolder:"Sanofi Belgium",medicineName:c,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Flemtrada"}],fdaDrugLabel:[{brand:d,indication:"1 INDICATIONS AND USAGE CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). ( 1 )",manufacturer:e,splSetId:"4f5f7255-7abc-4328-bd1a-ceaf139ef3e0"},{brand:"LEMTRADA",indication:"1 INDICATIONS AND USAGE LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS [see Warnings and Precautions (5) ] . LEMTRADA is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS [see Warnings and Precautions (5) ] . ( 1 ) Limitations of Use : LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile [see Warnings and Precautions (5) ] . ( 1 ) Limitations of Use LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile [see Warnings and Precautions (5) ].",manufacturer:e,splSetId:"6236b0bc-82e9-4447-9a78-f57d94770269"}],id:a,nciThesaurus:{casRegistry:"216503-57-0",chebiId:f,chemicalFormula:f,definition:"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system.",fdaUniiCode:"3A189DH42V",identifier:"C1681",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C72960"],synonyms:["ALEMTUZUMAB",a,"Anti-CD52 Monoclonal Antibody",d,"Campath-1H","LDP-03",c,"MabCampath","Monoclonal Antibody Campath-1H",b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAlemtuzumab",extension:".json",createdAt:g,updatedAt:g}}],fetch:{},mutations:void 0}}("Alemtuzumab","alemtuzumab","Lemtrada","Campath","Genzyme Corporation","","2021-10-30T13:35:51.753Z")));